X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2019-01-30 | TCDA | Coufal Sandra I | Dir, 10% | S - Sale | $20.10 | -28 | 7,387,860 | 0% | -$563 | ||||||
D | 2019-01-28 | TCDA | Veitinger Klaus R Dr | Dir | S - Sale+OE | $20.31 | -6,000 | 226,324 | -3% | -$121,880 | |||||
M | 2019-01-28 | TCDA | Coufal Sandra I | Dir, 10% | S - Sale | $20.22 | -1,972 | 7,387,888 | 0% | -$39,877 | |||||
D | 2019-01-25 | TCDA | Veitinger Klaus R Dr | Dir | S - Sale+OE | $20.86 | -6,000 | 230,324 | -3% | -$125,180 | |||||
2019-01-07 | TCDA | Otto Dawn Parsell | SVP, Clinical Development | S - Sale | $23.27 | -665 | 0 | -100% | -$15,475 | ||||||
2019-01-02 | TCDA | Lockey Claire | Chief Dev. Officer, SVP | S - Sale | $23.59 | -684 | 0 | -100% | -$16,136 | ||||||
D | 2018-12-27 | TCDA | Veitinger Klaus R Dr | Dir | S - Sale+OE | $23.71 | -2,437 | 234,324 | -1% | -$57,773 | |||||
2018-12-26 | TCDA | Klaerner Gerrit | Pres, CEO | S - Sale | $25.02 | -4,000 | 848,472 | 0% | -$100,080 | ||||||
2018-12-26 | TCDA | Coufal Sandra I | Dir, 10% | S - Sale | $25.08 | -3,400 | 7,389,860 | 0% | -$85,272 | ||||||
D | 2018-12-26 | TCDA | Veitinger Klaus R Dr | Dir | S - Sale+OE | $24.97 | -9,814 | 235,764 | -4% | -$245,056 | |||||
D | 2018-12-26 | TCDA | Lockey Claire | Chief Dev. Officer, SVP | S - Sale+OE | $25.06 | -10,000 | 0 | -100% | -$250,600 | |||||
2018-11-13 | TCDA | Parker Geoffrey M. | Chief Fin. Officer, SVP | P - Purchase | $29.72 | +5,000 | 65,000 | +8% | +$148,600 | ||||||
D | 2018-07-02 | TCDA | Isern Brian M. | possible member of 10% group, 10% | P - Purchase | $19.00 | +463,158 | 7,150,936 | +7% | +$8,800,002 | |||||
D | 2018-07-02 | TCDA | Longitude Capital Partners Ii, LLC | 10% | P - Purchase | $19.00 | +131,579 | 5,907,889 | +2% | +$2,500,001 | |||||
D | 2018-07-02 | TCDA | Hirsch David | Dir | P - Purchase | $19.00 | +131,579 | 3,023,366 | +5% | +$2,500,001 | |||||
D | 2018-07-02 | TCDA | Orbimed Advisors LLC | Dir, 10% | P - Purchase | $19.00 | +368,421 | 10,889,280 | +4% | +$6,999,999 | |||||
D | 2018-07-02 | TCDA | Bonita David P | Dir, 10% | P - Purchase | $19.00 | +368,421 | 10,892,912 | +4% | +$6,999,999 | |||||
D | 2018-07-02 | TCDA | Coufal Sandra I | Dir, 10% | P - Purchase | $19.00 | +463,158 | 7,393,260 | +7% | +$8,800,002 | |||||
D | 2018-07-02 | TCDA | Falberg Kathryn E | Dir | P - Purchase | $19.00 | +31,579 | 35,211 | +869% | +$600,001 | |||||
2018-07-02 | TCDA | Pietzke Steffen | VP Fin, Chief Acct Officer | P - Purchase | $19.00 | +10,527 | 10,527 | New | +$200,013 | ||||||
2018-07-02 | TCDA | Van Beek Jeroen B | Chief Comm Officer, SVP | P - Purchase | $19.00 | +5,264 | 5,264 | New | +$100,016 | ||||||
2018-07-02 | TCDA | Stahl Wilhelm | Chief Tech Officer, SVP | P - Purchase | $19.00 | +13,158 | 13,158 | New | +$250,002 | ||||||
2018-07-02 | TCDA | Hejlek Edward J | SVP, GC, Secy. | P - Purchase | $19.00 | +13,158 | 13,158 | New | +$250,002 | ||||||
2018-07-02 | TCDA | Parker Geoffrey M. | Chief Fin. Officer, SVP | P - Purchase | $19.00 | +60,000 | 60,000 | New | +$1,140,000 | ||||||
2018-07-02 | TCDA | Klaerner Gerrit | Pres, CEO | P - Purchase | $19.00 | +15,790 | 852,472 | +2% | +$300,010 |
A | Amended filing |
D | Derivative transaction in filing (usually option exercise) |
E | Error detected in filing |
M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
S - Sale | Sale of securities on an exchange or to another person |
S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
P - Purchase | Purchase of securities on an exchange or from another person |